Overview

Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg)

Status:
Completed

Trial end date:
2001-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the tolerability, pharmacokinetic profile of BIA 3-202 and its metabolites, and the pharmacokinetic and pharmacodynamic interaction between 4 different single doses of BIA 3-202 (50 mg, 100 mg, 200 mg and 400 mg) and a single dose of standard levodopa 100 mg/benserazide 25 mg (Madopar® 125) in adult male and female healthy volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

Bial - Portela C S.A.

Treatments:

Benserazide
Benserazide, levodopa drug combination
Levodopa